Molbio Diagnostics IPO Eyes ₹940 Cr for Expansion and Stake Dilution

Molbio Diagnostics is set to launch an initial public offering (IPO) worth ₹940 crore, aiming to bolster its capital for expansion and reduce the promoter group's stake. The IPO includes a fresh issue of shares to raise ₹200 crore for capital expenditures, alongside a ₹740 crore offer for sale, which will see the promoter stake decrease from 46.6% to 43%.

Global Reach and Core Products

Established in 2000, Molbio Diagnostics has grown into a significant player in the molecular diagnostics field. Operating six manufacturing sites across India, the company serves over 90 countries worldwide, including partnerships with government health programs, diagnostic labs, and international healthcare organizations. A major portion of its revenue stems from its tuberculosis diagnostic test kits, which are part of its proprietary 'Truenat' platform. This portable diagnostic system is designed for use in resource-limited settings, providing accurate results within an hour.

Financial Performance and Growth

Molbio has demonstrated robust financial growth in recent years. Between FY24 and FY26, the company's revenue climbed by 31.5% annually, reaching ₹1,445.7 crore, while net profit surged by 40.2% to ₹164.1 crore. The company's EBITDA increased by 33.2% to ₹328.2 crore, with an EBITDA margin rising to 22.6% in FY26 from 22% in FY24. On a year-on-year basis, FY26 saw revenue grow by 41.7%, EBITDA rise by 27.9%, and net profit increase by 18.4%.

Market Position and Valuation

Despite the absence of directly comparable listed peers in India, Molbio Diagnostics positions itself competitively in the healthcare diagnostics and medical device sector. The company demands a price-earnings (P/E) multiple of up to 57, comparable to other industry players such as Poly Medicure, Dr. Lal PathLabs, and Metropolis Healthcare, which have P/E multiples ranging from 54 to 81.

Molbio's revenue model is heavily reliant on the sale of diagnostic test kits, contributing 74% of its total revenue, with tuberculosis test kits accounting for 70% of this figure. The company's strategic collaborations and subsidiary operations further enhance its offerings in radiology, digital pathology, and breast health screening solutions.

As Molbio Diagnostics prepares for its IPO, it presents an intriguing opportunity for high-risk investors seeking long-term growth in the dynamic molecular diagnostics industry.